142 related articles for article (PubMed ID: 30956760)
1. Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines.
Kittler JM; Sommer J; Fischer A; Britting S; Karg MM; Bock B; Atreya I; Heindl LM; Mackensen A; Bosch JJ
Oncotarget; 2019 Mar; 10(19):1812-1828. PubMed ID: 30956760
[TBL] [Abstract][Full Text] [Related]
2. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
3. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells.
Bosch JJ; Iheagwara UK; Reid S; Srivastava MK; Wolf J; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2010 Jan; 59(1):103-12. PubMed ID: 19557412
[TBL] [Abstract][Full Text] [Related]
4. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
[TBL] [Abstract][Full Text] [Related]
5. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes.
Damle NK; Klussman K; Linsley PS; Aruffo A
J Immunol; 1992 Apr; 148(7):1985-92. PubMed ID: 1372018
[TBL] [Abstract][Full Text] [Related]
6. Phorbol myristate acetate-activated keratinocytes stimulate proliferation of resting peripheral blood mononuclear lymphocytes via a MHC-independent, but protein kinase C- and intercellular adhesion molecule-1-dependent, mechanism.
Simon JC; Cruz PD; Bergstresser PR; Davis LS; Tigelaar RE
J Immunol; 1991 Jan; 146(2):476-84. PubMed ID: 1670943
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
8. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
9. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
Dezfouli S; Hatzinisiriou I; Ralph SJ
Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of human naive and memory T helper cells with bacterial superantigen. Naive CD4+45RA+ T cells require a costimulatory signal mediated through the LFA-1/ICAM-1 pathway.
Fischer H; Gjörloff A; Hedlund G; Hedman H; Lundgren E; Kalland T; Sjögren HO; Dohlsten M
J Immunol; 1992 Apr; 148(7):1993-8. PubMed ID: 1347547
[TBL] [Abstract][Full Text] [Related]
11. LFA-3 plasmid DNA enhances Ag-specific humoral- and cellular-mediated protective immunity against herpes simplex virus-2 in vivo: involvement of CD4+ T cells in protection.
Sin JI; Kim J; Dang K; Lee D; Pachuk C; Satishchandran C; Weiner DB
Cell Immunol; 2000 Jul; 203(1):19-28. PubMed ID: 10915558
[TBL] [Abstract][Full Text] [Related]
12. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
[TBL] [Abstract][Full Text] [Related]
13. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
14. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
15. Differential regulatory effects of intercellular adhesion molecule-1 on costimulation by the CD28 counter-receptor B7.
Damle NK; Klussman K; Linsley PS; Aruffo A; Ledbetter JA
J Immunol; 1992 Oct; 149(8):2541-8. PubMed ID: 1383317
[TBL] [Abstract][Full Text] [Related]
16. Costimulatory molecule expression on human uveal melanoma cells: functional analysis of CD40 and B7-H1.
Ma J; Usui Y; Kezuka T; Okunuki Y; Zhang L; An X; Mizota A; Goto H
Exp Eye Res; 2012 Mar; 96(1):98-106. PubMed ID: 22200489
[TBL] [Abstract][Full Text] [Related]
17. Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.
Ostrand-Rosenberg S; Horn LA; Alvarez JA
Cancer Immunol Immunother; 2015 Oct; 64(10):1287-93. PubMed ID: 25792524
[TBL] [Abstract][Full Text] [Related]
18. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
19. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
20. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
